BIOTRIP Token just entered the Real World

The project took form from the concomitant from BIOCASE Brazil on use of psychedelic substances, like psilocibina and psilocina, to treat mental illness and/or serious psychiatric issues.

According to the company's business plan, the entire commercial process related to the commercial product resulting from research with Psilocybe mushrooms will be anchored in the cryptocurrency. To acquire the product or the technology licensing in Brazil or in other parts of the world, the interested party must purchase through the company's cryptocurrency.

In Brazil, the product will probably only be available for hospitals, clinics and research centers, with sales online or not, but always wholesale and always by Legal Entities. The purchase of Crypto by Individuals will also be possible, but this type of buyer/investor will not be able to receive the final products, remaining only in possession of their cryptocurrencies.

The group is launching the BCASE token with the aim of carrying out transactions for the digital environment – ​​more secure, advantageous and decentralized. The token will be used to purchase Biocase Brasil's psychedelic substance products

The intent to launch the BCASE Token on Solana Network, for a faster and cheaper experience.

Our first study, now in 2nd Phase of clinical evaluation, encompasses the end of life that brings a very great psychological and social burden to the patient, and also to the people close to him. In addition to the pain and physical limitation resulting from the progression of diseases, the psychological suffering due to the pain itself, the fear of death, dependence and feelings of attachment and abandonment, has a great harmful impact on the quality of life of this patient. In this first study, we are addressing the therapeutic effects of Psilocybin in the treatment of Fear of Death, in addition to the evaluation of secondary endpoints such as depression and sleep quality. The study carried out by Dr. Cesar Camara, CEO of Biocase Brasil, includes cancer patients at risk of death, with low life expectancy and with anxiety disorders, according to clinical diagnosis (CID) and anxiety score through HADS and GAD-7.

One of the goals of cancer treatment is to promote the relief of physical and psychological symptoms of patients, especially when there is little possibility of cure, resulting in a better quality of life. The prevalence of anxiety and depression in these patients may vary according to the type of cancer, time of diagnosis, treatment site and life expectancy.

In a study carried out in 2019, the World Health Organization (WHO) pointed out that Brazil has, compared to all other countries in the world, the largest number of anxious people. There are 18.6 million Brazilians who suffer from some type of anxiety disorder. According to the epidemiological study, the lifetime prevalence of depression in Brazil is around 15.5%.
Moreover, Brazil has a legal structure that permits faster clinical trial development involving natural psychedelic presents in mushrooms and vegetables forbidden in other countries

The scientific journals "The New England Journal of Medicine" and "Nature" recently published consistent results of research on the use of psychedelics in the treatment of depression and post-traumatic stress.
The number of high reputable studies publisher grew 300% over the last 10 years.

Psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is an indole alkaloid compound derived from tryptophan, an agonist of serotonergic receptors and has an affinity for 5HT2A receptors. The substance is found in fungi, mainly in mushrooms of the Psilocybe cubensis family. The psychoactive substance present in mushrooms induces changes in sensory, behavioral, emotional and common sense perception about oneself, including reductions in depressive and anxiety symptoms. And these profoundly occurring changes are characteristic of an altered state of consciousness and may involve mystical-type experiences.

With the studies carried out, Biocase has a structure with the basic licenses for the production of the drug in partnership with the national laboratory CERTBIO – (Laboratory for the Evaluation and Development of Biomaterials of the Northeast) University of Paraíba, which will boost research, extraction and production substances for the purpose of treating patients in clinical conditions. Second step: Authorization for testing on animals and then on humans. Biocase has a Study and Research Center (CEP) in São Paulo suitable for carrying out Clinical Studies in Humans called Instituto Alma Viva;